ATE145241T1 - Polypeptid, das zur interaktion mit thrombin fähig ist - Google Patents

Polypeptid, das zur interaktion mit thrombin fähig ist

Info

Publication number
ATE145241T1
ATE145241T1 AT91202009T AT91202009T ATE145241T1 AT E145241 T1 ATE145241 T1 AT E145241T1 AT 91202009 T AT91202009 T AT 91202009T AT 91202009 T AT91202009 T AT 91202009T AT E145241 T1 ATE145241 T1 AT E145241T1
Authority
AT
Austria
Prior art keywords
thrombin
gla
amino acid
polypeptide
glu
Prior art date
Application number
AT91202009T
Other languages
English (en)
Inventor
Michitaka Zushi
Komakazu Gomi
Shuji Yamamoto
Koji Suzuki
Akio Matsuda
Original Assignee
Asahi Chemical Ind
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Chemical Ind filed Critical Asahi Chemical Ind
Application granted granted Critical
Publication of ATE145241T1 publication Critical patent/ATE145241T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/7455—Thrombomodulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT91202009T 1990-08-03 1991-08-05 Polypeptid, das zur interaktion mit thrombin fähig ist ATE145241T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP20497890 1990-08-03

Publications (1)

Publication Number Publication Date
ATE145241T1 true ATE145241T1 (de) 1996-11-15

Family

ID=16499445

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91202009T ATE145241T1 (de) 1990-08-03 1991-08-05 Polypeptid, das zur interaktion mit thrombin fähig ist

Country Status (9)

Country Link
US (1) US5574007A (de)
EP (1) EP0474273B1 (de)
KR (1) KR930008093B1 (de)
AT (1) ATE145241T1 (de)
AU (1) AU632958B2 (de)
CA (1) CA2048425C (de)
DE (1) DE69123106T2 (de)
ES (1) ES2093674T3 (de)
HK (1) HK1000968A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063763A (en) * 1989-04-28 2000-05-16 Schering Aktiengesellschaft Protease-resistant thrombomodulin analogs
US5780303A (en) * 1990-04-06 1998-07-14 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5672585A (en) * 1990-04-06 1997-09-30 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US6521594B1 (en) 1990-04-06 2003-02-18 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US6017877A (en) * 1990-04-06 2000-01-25 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5916874A (en) * 1994-04-20 1999-06-29 Asahi Kasei Kogyo Kabushiki Kaisha Method for treating liver injury
CA2292759A1 (en) * 1997-06-05 1998-12-10 Abbott Laboratories Reagents and methods useful for detecting diseases of the urinary tract
WO2003033515A1 (en) * 2001-10-15 2003-04-24 Corixa Corporation Compositions and methods for the therapy and diagnosis of acne vulgaris
JP4340540B2 (ja) * 2002-01-18 2009-10-07 旭化成ファーマ株式会社 可溶性トロンボモジュリン高濃度含有製剤
US6706068B2 (en) 2002-04-23 2004-03-16 Bret A. Ferree Artificial disc replacements with natural kinematics
US7579000B2 (en) 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
CN100412090C (zh) * 2002-05-01 2008-08-20 舍林股份公司 作为抗凝剂的新的靶向组织因子的血栓调节蛋白融合蛋白
MX2009003384A (es) * 2006-10-06 2009-04-08 Asahi Kasei Pharma Corp Agente terapeutico y/o de mejoramiento para la coagulacion intravascular diseminada.
CA2681294C (en) 2007-03-23 2014-05-06 Asahi Kasei Pharma Corporation Method for producing high-purity soluble thrombomodulin
JP2011178687A (ja) * 2010-02-26 2011-09-15 Kochi Univ 造血細胞移植に伴う疼痛の予防および／または治療剤
NZ602852A (en) 2010-04-30 2014-03-28 Asahi Kasei Pharma Corp Highly-purified soluble thrombomodulin and method for producing same
PT2781221T (pt) 2011-11-15 2020-06-01 Asahi Kasei Pharma Corp Medicamento para tratamento e/ou melhoria de sepsia
BR112021007460A2 (pt) 2018-10-22 2021-11-03 Asahi Kasei Pharma Corp Medicamento para tratamento terapêutico e/ou melhora de um paciente com sepse
CN112608965B (zh) * 2021-01-15 2022-08-05 华东理工大学 利用深海链霉菌生产怡莱霉素e的培养基及其制备方法
CN113429459B (zh) * 2021-06-16 2022-07-26 昆明医科大学第一附属医院 一种抗血小板多肽及其药物组合物与其应用
AU2023230867A1 (en) * 2022-01-07 2024-06-06 Regents Of The University Of Minnesota Hemostatic composition containing recombinant human clotting factors, and method of producing
CN120365400B (zh) * 2025-06-26 2025-10-31 山东大学 一种东亚钳蝎来源多肽及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0312598B1 (de) * 1987-01-08 1999-05-26 Asahi Kasei Kogyo Kabushiki Kaisha Peptid zur beschleunigung der wirkung des proteins-c mit thrombin
DK299087D0 (da) * 1987-06-12 1987-06-12 Novo Industri As Proteins and derivatives thereof
WO1991004276A1 (en) * 1989-09-25 1991-04-04 Asahi Kasei Kogyo Kabushiki Kaisha Isolated, physiologically active human thrombomodulin polypeptide

Also Published As

Publication number Publication date
ES2093674T3 (es) 1997-01-01
DE69123106T2 (de) 1997-04-10
KR920004419A (ko) 1992-03-27
CA2048425C (en) 1998-04-21
HK1000968A1 (en) 1998-05-15
EP0474273A2 (de) 1992-03-11
CA2048425A1 (en) 1992-02-04
DE69123106D1 (de) 1996-12-19
US5574007A (en) 1996-11-12
AU632958B2 (en) 1993-01-14
EP0474273A3 (en) 1992-04-08
KR930008093B1 (ko) 1993-08-25
EP0474273B1 (de) 1996-11-13

Similar Documents

Publication Publication Date Title
AU632958B2 (en) A polypeptide capable of interacting with thrombin
DK473888A (da) Peptid, fremgangsmaade til fremstilling deraf og laegemiddel indeholdende peptidet
DE3650540D1 (de) Antigene Proteine und diese enthaltende Impfstoffe zur Verhütung von Kokzidiose
DE3587512D1 (de) Huellenantigene vom menschlichen immunodefizienz-virus und deren verwendungen.
HU902697D0 (en) Process for the enzymatic removal of the n-terminal sequence of proteins
KR890003802A (ko) 재조합 dna 기술에 의해 제조된 소의 췌장 트립신 억제제, 그 제조 방법, 발현 벡터 및 재조합 숙주 및 그의 제약적 용도
IT1153265B (it) Polipeptidi contenenti la sequenza degli amminoacidi dell'interferone umano immune (interferone umano gamma), relativi veicoli di espressione, loro procedimento di preparazione, composizioni farmaceutiche contenenti tali polipeptidi
DE69426019D1 (de) Stabile bakterizide proteine, welche die permeabilität erhöhen und pharmazeutische zusammensetzungen, diese enthaltend
EP0378641A4 (en) Novel antimicrobial peptide, compositions containing same and uses thereof
NZ228710A (en) Modified "echistatin" and anti-clotting pharmaceutical composition
EP0257312A3 (de) Vom Knorpel abstammende Leukozytenelastase hemmende Substanz
HUT50195A (en) New peptites hindering the activity of immune system and medical compositions containing them and process for production of these peptides and compositions
DK370489D0 (da) Rekombinant humant interleukin-2, dets fremstilling og anvendelse som laegemiddel
SE8801723D0 (sv) Fibronectin binding protein as well as its preparation
ATE108833T1 (de) Antikörper gegen fibrin, immunogene peptide für die herstellung dieser antikörper, verfahren zur bestimmung von fibrin und pharmazeutische zubereitungen auf der basis dieser antikörper.
EP0723016A3 (de) Leukocyten-aktivierender Faktor
CA2006929A1 (en) Cloning and production of polypeptide analogs of human fibronectin and methods of using such polypeptide analogs
DE69432724D1 (de) HST-2 Mutein, dafür kodierende DNS und Herstellung
DE68917520D1 (de) Verfahren und Systeme zur Herstellung von HIV-Antigenen.
ATE108207T1 (de) Polypeptide und dafür kodierende dna.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee